Diuretic-Enhanced Dual-Phase F-18 FDG PET/CT: A New Window Into Muscle-Invasive Bladder Cancer Authors: Cihan Şin, Burcu Esen Akkaş, Özge Vural Topuz, Özgür Omak, Enes M. Kaya, Harun Özdemir, Begüm Çalım Gürbüz, Halil L. Canat, Abdulmuttalip Şimşek, Meryem Kaya Published: 2026 ABSTRACT ObjectiveThis study aimed to assess the diagnostic performance of diuretic-enhanced dual-phase F-18 FDG PET/CT in detecting muscle invasion in bladder cancer (BC) and to evaluate the predictive role of metabolic and volumetric PET parameters.Methods A total of 105 patients (85 males, 20 females; mean age: 67.8 years) with suspected BC underwent F-18 FDG PET/CT for initial staging. Routine and delayed pelvic imaging was performed after intravenous furosemide. Metabolic and volumetric parameters, including SUV max , SUV mean , metabolic tumor volume (MTV), and total lesion glycolysis (TLG), were measured and correlated with histopathological findings. Statistical analyses consisted of Mann–Whitney U, Kruskal–Wallis, and Receiver operating characteristic (ROC) curve analysis. Results Distant metastases were detected in 30 patients (28.5%), which directly influenced treatment decisions. In the TUR-B cohort ( n = 75), F-18 FDG PET/CT demonstrated a sensitivity of 78.0%, specificity of 62.5%, positive predictive value of 88.5%, negative predictive value of 43.5%, and an overall accuracy of 74.7% in differentiating malignant from benign bladder lesions. Among the 59 patients with confirmed malignancy, volumetric parameters correlated with pathological T-stage. Patients with T2 tumors had significantly higher SUV max , SUV mean , MTV, and TLG values compared with 8.15 predicted T2 tumors with 85% sensitivity and 75% specificity ( Fig. 3A ). ( A ) ROC curve analysis of MTV for predicting T2 tumors in patients undergoing TUR-B showed an AUC of 0.814 (95% CI: 0.69–0.94). An MTV cutoff value > 8.15 predicted T2 tumors with 85% sensitivity and 75% specificity. ( B ) ROC curve analysis of TLG for predicting T2 tumors in patients undergoing TUR-B showed an AUC of 0.830 (95% CI: 0.71–0.95). A TLG cutoff value > 52.30 predicted T2 tumors with 95% sensitivity and 72% specificity. ROC curve analysis of TLG for predicting T2 tumors in patients undergoing TUR-B showed an AUC of 0.830 (95% CI: 0.71–0.95). A TLG cutoff value > 52.30 predicted T2 tumors with 95% sensitivity and 72% specificity ( Fig. 3B ). Discussion Accurate assessment of muscle invasion represents a fundamental step in the management of BC, as it significantly influences therapeutic decision-making and patient prognosis. Patients with NMIBC can often be treated effectively with TUR of the bladder tumor (TUR-B) followed by intravesical therapy. In contrast, muscle invasion constitutes an adverse prognostic factor that is associated with increased recurrence rates and reduced survival. For MIBC, the standard of care remains radical cystectomy combined with pelvic lymphadenectomy, yielding an overall survival rate of approximately 50%. 3 13 Given the prognostic implications of muscle invasion, its early and reliable identification is crucial for implementing personalized treatment strategies. The use of the standardized Vesical Imaging-Reporting and Data System has high sensitivity and specificity in detecting MIBC. 12 However, even with the improved magnetic resonance imaging (MRI) technology, which provides almost excellent soft tissue resolution, neglecting the need for TUR before radical surgery based on MRI findings is a debated issue. 14 The correlation of various quantitative tumor parameters such as MTV and TLG with aggressive tumor features and advanced tumor stages has been demonstrated in a variety of malignancies. Likewise, several studies have suggested that FDG PET/CT can be beneficial for selecting high-risk BC patients preoperatively. However, its clinical role in risk stratification of such patients is not well defined. Furthermore, the value of MTV and TLG and the corresponding optimal cutoffs for the prediction of tumor stage and prognosis are largely unexplored. In this study, we observed a statistically significant positive correlation between volumetric metabolic parameters and tumor size, which corresponded to higher pathological T stages. Elevated SUV max , MTV, and TLG values were indicative of increased tumor burden and biological aggressiveness, supporting their role as potential surrogate biomarkers for muscle invasion in BC. In the TUR-B cohort, these parameters were lowest in Ta-stage tumors and highest in T2-stage tumors, highlighting their clinical relevance in accurate preoperative T-stage stratification. In the present prospective study, we considered that these volumetric quantitative tumor parameters obtained from the staging PET/CT may have a role in diagnosing patients with MIBC and help guide personalized treatment in patients with BC. Due to the scarcity of existing data, we sought to establish preoperative cutoff values using diuretic-enhanced F-18 FDG PET/CT. We observed that both MTV and TLG were significantly elevated in the muscle-invasive group. Specifically, an MTV > 8.15 cm 3 and TLG > 52.3 were associated with high diagnostic accuracy for detecting T2 disease. In clinical practice, F-18 FDG PET/CT is primarily utilized for staging locally advanced disease following TUR-B, identifying distant metastases, and detecting locoregional or systemic recurrence during follow-up. 15 Notably, F-18 FDG PET/CT has demonstrated superiority over conventional radiologic methods in the detection of distant metastases. 16 In accordance with previous studies, our analysis revealed distant organ metastases in 28.5% of patients during initial staging, leading to significant alterations in therapeutic planning. 17 In fact, BC is an FDG-avid tumor and a recent meta-analysis reported the pooled sensitivity and specificity of FDG PET/CT in detecting BC as 80 and 84%, respectively. Despite these figures, F-18 FDG PET/CT does not outperform cross-sectional imaging modalities such as CT or MRI in the evaluation of primary bladder tumors and therefore remains inadequate for accurate local (T) staging. 18 Accordingly, its utility is largely restricted to the assessment of metastatic disease in the setting of MIBC. At present, MRI and computed tomography (CT) remain the most widely employed conventional imaging modalities for local (T) staging of BC. Takeuchi et al demonstrated that diffusion-weighted MRI provides sufficient tissue contrast to differentiate muscle-invasive (T2) lesions from nonmuscle-invasive tumors (Tis, Ta, T1). 19 Conversely, while CT imaging has proven effective in identifying advanced-stage disease (T3/T4), it lacks the spatial and soft tissue resolution necessary to reliably discriminate between T1 and T2 lesions. 20 The role of F-18 FDG PET/CT in local T-staging remains limited, partially due to the excretion of FDG into the urinary tract, which can obscure visualization of bladder wall lesions. To overcome this issue, forced diuresis and delayed imaging have been shown to improve the diagnostic performance of FDG PET/CT. In a prospective study conducted by Nayak et al, diuretic-enhanced F-18 FDG PET/CT demonstrated superior diagnostic accuracy compared with contrast-enhanced CT, particularly in the detection of primary bladder tumors and regional LN metastases. These findings suggest that incorporating a forced diuresis protocol may enhance the performance of F-18 FDG PET/CT in the local staging of BC and offer a more reliable alternative to conventional imaging modalities. 11 In our study, consistent with previously reported literature, furosemide-induced diuresis combined with delayed pelvic F-18 FDG PET/CT imaging effectively reduced urinary tracer accumulation within the bladder, thereby enhancing the delineation of bladder tumors from adjacent tissues ( Fig. 2 ). In this study, we evaluated the diagnostic performance of F-18 FDG PET/CT in differentiating malignant from benign bladder lesions. Our findings demonstrated a sensitivity of 78%, specificity of 62.5%, positive predictive value of 88.5%, negative predictive value of 43.5%, and an overall accuracy of 74.7%. These results suggest that PET/CT is a valuable diagnostic tool, particularly for confirming malignancy, although its limited specificity and negative predictive value indicate restricted reliability in excluding BL. 21 In this prospective study, histopathological examination revealed benign pathology in 16 patients. Among this group, two patients had granulomatous diseases that mimicked malignancy in both MR and PET/CT images with significantly higher metabolic and volumetric parameters compared with the others. Ma et al reported that granulomatous reactions developing following intravesical Bacille Calmette-Guérin therapy for BC show similarities to malignant neoplastic processes on radiological imaging, complicating differential diagnosis and posing significant challenges in clinical management. 22 Our study demonstrated a statistically significant positive correlation between volumetric and metabolic parameters derived from PET imaging and tumor size, which corresponded to higher pathological T stages. Elevated SUV max , MTV, and TLG values were indicative of increased tumor burden and biological aggressiveness, supporting their role as potential surrogate biomarkers for muscle invasion in BC. In the TUR-B cohort, these parameters were lowest in Ta-stage tumors and highest in T2-stage tumors, highlighting their clinical relevance in accurate preoperative T-stage stratification. A meta-analysis by Lu et al confirmed the diagnostic efficacy of F-18 FDG PET/CT for metastatic disease, yet emphasized the paucity of evidence supporting its role in detecting detrusor muscle invasion in contrast to the results of our study. 23 Also, in a prospective evaluation, Sharma et al analyzed dynamic F-18 FDG PET/CT imaging at various time points but found no consistent correlation between SUV max and tumor stage (Ta–T4). 24 Similarly, Li et al reported limited sensitivity of F-18 FDG PET/CT in detecting Ta–T3 tumors, with relatively improved performance in T4 lesions among 73 patients undergoing preoperative evaluation prior to radical cystectomy. 25 We considered that the use of diuretic-enhanced delayed pelvic images as the standardized study protocol contributed to the higher detection rates of T2 tumors in the study group. The prospective study design enabled systematic data acquisition and longitudinal follow-up, thereby improving the reliability and clinical relevance of prognostic PET/CT parameters. To our knowledge, this investigation represents one of the largest prospective studies focused specifically on F-18 FDG PET/CT–derived volumetric and metabolic parameters in the preoperative assessment of muscle-invasive BC. Accurate discrimination between nonmuscle-invasive and muscle-invasive BC is clinically critical, as the treatment strategies for these two groups differ substantially. 3 In current practice, local staging is based primarily on histopathological evaluation of TURBT specimens and multiparametric MRI 20 ; however, understaging and delays in definitive treatment remain important clinical challenges. In this context, our study showed that MTV, TLG, and SUV-based parameters derived from delayed diuretic-enhanced FDG PET/CT may contribute to identifying patients with a high likelihood of detrusor muscle invasion. Nevertheless, these parameters should not be considered replacements for TURBT or MRI, but rather adjunctive decision-support tools that may help guide the need for re-TURBT, earlier multidisciplinary evaluation, and definitive treatment planning, particularly in cases with equivocal local staging. Although the present study is a prospective one, there are some limitations. The relatively small sample size, single-center design, and uneven distribution of tumor stages and histological subtypes may have negatively contributed to the results. Moreover, variability in VOI delineation—particularly in irregular lesions or those adjacent to normal tissue—may have impacted the accuracy of volumetric measurements. A limitation of our study is that VOIs were manually drawn in three planes by a single reader, and inter-observer reproducibility was not assessed. Therefore, potential variability related to observer dependency could not be fully excluded. Conclusion Our study demonstrates that diuretic-enhanced dual-phase F-18 FDG PET/CT may provide complementary information in the staging of patients with known or suspected BC, not only for the detection of distant metastases but also for identifying patients at higher risk of muscle-invasive disease. PET-derived metabolic and volumetric parameters may contribute to preoperative risk stratification and treatment planning. However, these findings require validation in larger prospective studies with long-term follow-up before their role in routine clinical practice can be more clearly established.